PhoQ Mutations Promote Lipid A Modification and Polymyxin Resistance of Pseudomonas aeruginosa Found in Colistin-Treated Cystic Fibrosis Patients

Pseudomonas aeruginosa can develop resistance to polymyxin and other cationic antimicrobial peptides. Previous work has shown that mutations in the PmrAB and PhoPQ regulatory systems can confer low to moderate levels of polymyxin resistance (MICs of 8 to 64 mg/liter) in laboratory and clinical strai...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Antimicrobial Agents and Chemotherapy 2011-12, Vol.55 (12), p.5761-5769
Hauptverfasser:	Miller, Amanda K, Brannon, Mark K, Stevens, Laurel, Johansen, Helle Krogh, Selgrade, Sara E, Miller, Samuel I, Høiby, Niels, Moskowitz, Samuel M
Format:	Artikel
Sprache:	eng
Schlagworte:	alleles Anti-Bacterial Agents Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use antibiotic resistance Antibiotics. Antiinfectious agents. Antiparasitic agents antimicrobial cationic peptides Bacterial Proteins Bacterial Proteins - genetics Biological and medical sciences colistin Colistin - pharmacology Colistin - therapeutic use Cystic Fibrosis Cystic Fibrosis - drug therapy Cystic Fibrosis - microbiology Drug Resistance, Bacterial Drug Resistance, Bacterial - genetics Errors of metabolism Female Humans lipid A Lipid A - chemistry loci Male Mechanisms of Resistance Medical sciences Metabolic diseases Microbial Sensitivity Tests Miscellaneous hereditary metabolic disorders Mutation operon patients Pharmacology. Drug treatments Polymyxins Polymyxins - pharmacology Polymyxins - therapeutic use Pseudomonas aeruginosa Pseudomonas aeruginosa - drug effects Pseudomonas aeruginosa - genetics Pseudomonas aeruginosa - metabolism Pseudomonas Infections - drug therapy Pseudomonas Infections - microbiology transcription (genetics)
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!